Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:SPPI
- CUSIP: 84763A10
- Web: www.sppirx.com
Capitalization:- Market Cap: $798.55 million
- Outstanding Shares: 78,576,000
Average Prices:- 50 Day Moving Avg: $8.10
- 200 Day Moving Avg: $6.76
- 52 Week Range: $3.21 - $9.70
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.90
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $132.03 million
- Price / Sales: 5.59
- Book Value: $2.53 per share
- Price / Book: 3.72
Profitability:- EBIDTA: ($44,850,000.00)
- Net Margins: -59.33%
- Return on Equity: -30.95%
- Return on Assets: -16.67%
Debt:- Debt-to-Equity Ratio: 0.56%
- Current Ratio: 3.08%
- Quick Ratio: 2.93%
Misc:- Average Volume: 792,330 shs.
- Beta: 1.49
- Short Ratio: 11.48
Frequently Asked Questions for Spectrum Pharmaceuticals (NASDAQ:SPPI)
What is Spectrum Pharmaceuticals' stock symbol?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. The company earned $34.30 million during the quarter, compared to analysts' expectations of $30.50 million. Spectrum Pharmaceuticals had a negative net margin of 59.33% and a negative return on equity of 30.95%. Spectrum Pharmaceuticals's revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.35) earnings per share. View Spectrum Pharmaceuticals' Earnings History.
Where is Spectrum Pharmaceuticals' stock going? Where will Spectrum Pharmaceuticals' stock price be in 2017?
4 equities research analysts have issued twelve-month price objectives for Spectrum Pharmaceuticals' stock. Their predictions range from $9.00 to $14.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $11.00 in the next year. View Analyst Ratings for Spectrum Pharmaceuticals.
What are analysts saying about Spectrum Pharmaceuticals stock?
Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Spectrum reported encouraging Q2 results, beating estimates for both sales and earnings. The company's progress with its lead pipeline candidate, Rolontis has been quite impressive. The company expects top-line data from a pivotal study and plans to file a BLA in 2018. However, Spectrum’s efforts to gain approval for Qapzola (bladder cancer) in the U.S. suffered a setback with the FDA issuing a complete response letter (CRL) in Nov 2016. Additional issues on the regulatory/development front could affect the stock. Also, low product sales remain a cause of concern. On the flip side, with the company entering into out-licensing agreements for a number of products, it will now be able to focus on Evomela and the development of its pipeline candidates. Spectrum’s shares have outperformed the industry so far this year." (8/18/2017)
- 2. Jefferies Group LLC analysts commented, "SPPI is undervalued based on Rolontis' LT promise in chemotherapy-induced neutropenia. We see 50%+ share upside as Rolontis' Ph. III program is lower risk (with data in H1 2018) and we believe its profile, senior management's oncology experience, and CIN market dynamics should enable Rolontis to gain meaningful market share from Neulasta. Poziotinib in mBC/NSCLC bears watching and offers pipeline optionality. Assume at Buy and $7.50 PT." (2/10/2017)
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include Foundation Medicine (FMI), Medpace Holdings (MEDP), Global Blood Therapeutics (GBT), Esperion Therapeutics (ESPR), Momenta Pharmaceuticals (MNTA), Genus plc (GNS), Genomic Health (GHDX), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Albany Molecular Research (AMRI), Immunomedics (IMMU), BeyondSpring (BYSI), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Cellectis S.A. (CLLS), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA) and Crispr Theraptc (CRSP).
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the folowing people:
- Rajesh C. Shrotriya M.D., Chairman of the Board, Chief Executive Officer
- Joseph W. Turgeon, President, Chief Operating Officer
- Kurt A. Gustafson, Chief Financial Officer, Executive Vice President
- Luigi Lenaz M.D., Lead Independent Director
- Gilles R. Gagnon, Director
- Raymond Wayne Cohen, Independent Director
- Stuart M. Krassner, Independent Director
- Anthony E. Maida III, Ph.D., Independent Director
Who owns Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.29%), Renaissance Technologies LLC (7.73%), State Street Corp (3.84%), Dimensional Fund Advisors LP (3.41%), Macquarie Group Ltd. (2.86%) and Goldman Sachs Group Inc. (1.60%). View Institutional Ownership Trends for Spectrum Pharmaceuticals.
Who sold Spectrum Pharmaceuticals stock? Who is selling Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Prudential Financial Inc., Numeric Investors LLC, Schwab Charles Investment Management Inc., Granite Investment Partners LLC, Piermont Capital Management Inc., Voya Investment Management LLC and SG Americas Securities LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.
Who bought Spectrum Pharmaceuticals stock? Who is buying Spectrum Pharmaceuticals stock?
Spectrum Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Dimensional Fund Advisors LP, Renaissance Technologies LLC, Macquarie Group Ltd., Kennedy Capital Management Inc., Wells Fargo & Company MN, Cornerstone Capital Management Holdings LLC. and Vanguard Group Inc.. View Insider Buying and Selling for Spectrum Pharmaceuticals.
How do I buy Spectrum Pharmaceuticals stock?
Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spectrum Pharmaceuticals' stock price today?
One share of Spectrum Pharmaceuticals stock can currently be purchased for approximately $9.40.
MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Spectrum Pharmaceuticals (NASDAQ:SPPI)Earnings History by Quarter for Spectrum Pharmaceuticals (NASDAQ SPPI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/3/2017 | Q2 2017 | ($0.27) | ($0.26) | $30.50 million | $34.30 million | View | Listen |  |
| 5/2/2017 | Q1 2017 | ($0.20) | ($0.18) | $32.23 million | $29.10 million | View | Listen | |
| 3/8/2017 | Q4 2016 | ($0.27) | ($0.22) | $31.13 million | $35.24 million | View | Listen | |
| 11/14/2016 | Q3 2016 | ($0.30) | ($0.22) | $29.53 million | $33.39 million | View | N/A | |
| 8/9/2016 | Q216 | ($0.29) | ($0.05) | $30.88 million | $33.90 million | View | N/A | |
| 5/5/2016 | Q1 | ($0.32) | ($0.14) | $28.83 million | $43.90 million | View | N/A | |
| 3/9/2016 | Q415 | ($0.18) | ($0.06) | $33.87 million | $50.30 million | View | N/A | |
| 11/4/2015 | Q315 | ($0.25) | ($0.28) | $31.87 million | $28.46 million | View | N/A | |
| 8/6/2015 | Q215 | ($0.22) | ($0.01) | $34.48 million | $44.98 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.06) | ($0.07) | $48.00 million | $38.60 million | View | N/A | |
| 3/13/2015 | Q414 | ($0.16) | $0.09 | $48.50 million | $51.70 million | View | N/A | |
| 11/6/2014 | Q314 | ($0.17) | $0.08 | $45.00 million | $47.99 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.09) | $0.09 | $41.50 million | $46.90 million | View | Listen | |
| 5/8/2014 | Q114 | ($0.22) | $0.01 | $39.49 million | $40.10 million | View | Listen | |
| 3/6/2014 | Q313 | ($0.11) | $0.05 | $41.96 million | $41.50 million | View | Listen | |
| 11/12/2013 | Q3 | ($0.07) | ($0.13) | $38.70 million | $42.44 million | View | Listen | |
| 8/7/2013 | Q2 2013 | ($0.12) | ($0.08) | $33.41 million | $33.23 million | View | N/A | |
| 5/9/2013 | Q1 2013 | ($0.32) | ($0.06) | | | View | N/A | |
| 11/7/2012 | Q312 | $0.29 | $0.42 | $68.56 million | $69.00 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Spectrum Pharmaceuticals (NASDAQ:SPPI)2017 EPS Consensus Estimate: ($0.97)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.21) | ($0.21) | ($0.21) |
| Q2 2017 | 2 | ($0.27) | ($0.23) | ($0.25) |
| Q3 2017 | 2 | ($0.25) | ($0.25) | ($0.25) |
| Q4 2017 | 2 | ($0.27) | ($0.24) | ($0.26) |
(Data provided by Zacks Investment Research)
Dividend History by Quarter for Spectrum Pharmaceuticals (NASDAQ SPPI)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 12/11/2012 | special | $0.15 | | 12/18/2012 | 12/20/2012 | 12/28/2012 |
(Data available from 1/1/2013 forward)
Headline Trends for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Latest Headlines for Spectrum Pharmaceuticals (NASDAQ:SPPI)
| Source: |
|
| Date | Headline |
|---|
 | Spectrum Pharmaceuticals, Inc. (SPPI) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - August 17 at 10:40 PM |
 | Spectrum Pharma (SPPI) Reports Initiation of Registrational Phase 3 Trial of Qapzola in Patients with Non-Muscle ... - StreetInsider.com
www.streetinsider.com - August 15 at 7:12 AM |
 | Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
finance.yahoo.com - August 15 at 7:12 AM |
| Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Expected to Announce Quarterly Sales of $29.86 Million
www.americanbankingnews.com - August 14 at 9:52 AM |
| Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 5 at 12:46 AM |
 | Why Spectrum Pharmaceuticals Stock Is Bolting Higher Today
www.fool.com - August 4 at 3:10 PM |
 | Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update - Business Wire (press release)
www.businesswire.com - August 4 at 8:28 AM |
| Spectrum Pharma (SPPI) Completes Enrollment in Phase 3 Pivotal Study of ROLONTIS - StreetInsider.com
www.streetinsider.com - August 1 at 9:11 PM |
 | BRIEF-Spectrum Pharmaceuticals announces enrollment in Rolontis phase 3 advance pivotal study
www.reuters.com - August 1 at 4:09 PM |
| Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS™ (eflapegrastim), a Novel Long-Acting GCSF
finance.yahoo.com - August 1 at 4:09 PM |
| $31.20 Million in Sales Expected for Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) This Quarter
www.americanbankingnews.com - July 27 at 3:05 PM |
| Spectrum Pharmaceuticals, Inc. (SPPI) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 25 at 8:40 PM |
| Zacks: Brokerages Anticipate Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to Announce -$0.26 EPS
www.americanbankingnews.com - July 25 at 9:03 AM |
| Head-To-Head Comparison: Spectrum Pharmaceuticals (SPPI) versus Nabriva Therapeutics AG (NBRV)
www.americanbankingnews.com - July 20 at 8:22 PM |
 | SUPN Crosses Above Average Analyst Target
www.nasdaq.com - July 13 at 9:49 AM |
| Alnylam and Sanofi Genzyme Initiate ATLAS Phase 3 Program with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B with or without Inhibitors
www.businesswire.com - July 8 at 7:27 PM |
| Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - July 5 at 12:12 PM |
| Spectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - June 30 at 1:44 PM |
| Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Quarterly Sales of $31.20 Million
www.americanbankingnews.com - June 30 at 11:23 AM |
| Brokerages Expect Spectrum Pharmaceuticals, Inc. (SPPI) to Post -$0.26 Earnings Per Share
www.americanbankingnews.com - June 29 at 12:38 AM |
| Spectrum Pharma (SPPI) Highlights Results of Combination Study of FOLOTYN Plus Romidepsin Presented at ICML - StreetInsider.com
www.streetinsider.com - June 19 at 9:29 AM |
| Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting
finance.yahoo.com - June 19 at 9:29 AM |
| BRIEF-Spectrum Pharmaceuticals says stockholders did not approve by advisory vote executive compensation at annual meeting
www.reuters.com - June 17 at 6:21 AM |
| Spectrum Pharmaceuticals, Inc. (SPPI) Given a $9.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - June 11 at 7:52 AM |
| Spectrum Pharmaceuticals, Inc. (SPPI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - June 6 at 1:04 PM |
| Spectrum Pharmaceuticals, Inc. (SPPI) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 5 at 12:47 PM |
| Analysts Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Quarterly Sales of $31.20 Million
www.americanbankingnews.com - June 4 at 7:34 AM |
| -$0.26 Earnings Per Share Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter
www.americanbankingnews.com - June 2 at 10:30 PM |
| Spectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017
finance.yahoo.com - June 2 at 8:01 AM |
| Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 Global Healthcare Conference on June 6th
finance.yahoo.com - May 30 at 9:01 AM |
| Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017 Health Care Conference on May 17
finance.yahoo.com - May 16 at 9:02 AM |
| Spectrum Pharmaceuticals, Inc. (SPPI) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 11 at 4:40 PM |
| Spectrum Pharmaceuticals, Inc. (SPPI) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 11 at 3:32 PM |
| Zacks: Brokerages Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Quarterly Sales of $31.2 Million
www.americanbankingnews.com - May 11 at 11:36 AM |
| Brokerages Anticipate Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Earnings of -$0.26 Per Share
www.americanbankingnews.com - May 9 at 12:30 PM |
| Spectrum Pharmaceuticals, Inc. to Post Q2 2017 Earnings of ($0.27) Per Share, Jefferies Group Forecasts (SPPI)
www.americanbankingnews.com - May 5 at 7:46 AM |
| Spectrum Pharmaceuticals, Inc. Forecasted to Post Q2 2017 Earnings of ($0.23) Per Share (SPPI)
www.americanbankingnews.com - May 5 at 7:46 AM |
| FY2020 EPS Estimates for Spectrum Pharmaceuticals, Inc. (SPPI) Raised by Jefferies Group
www.americanbankingnews.com - May 4 at 8:04 PM |
| Spectrum Pharmaceuticals, Inc. (SPPI) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - May 3 at 10:54 PM |
| Spectrum Pharmaceuticals (SPPI) Earns Media Impact Rating of 0.14
www.americanbankingnews.com - May 3 at 10:44 PM |
| Spectrum Pharmaceuticals, Inc. (SPPI) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 3 at 5:00 PM |
| Why Spectrum Pharmaceuticals Stock Is Sinking Today
www.fool.com - May 3 at 1:19 PM |
 | Spectrum Pharmaceuticals -7% off Q1 earnings miss
seekingalpha.com - May 2 at 7:43 PM |
 | Spectrum Pharma reports 1Q loss
marketbeat.com - May 2 at 6:13 PM |
| Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update - Yahoo Finance
finance.yahoo.com - May 2 at 5:48 PM |
| Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update
finance.yahoo.com - May 2 at 5:48 PM |
| Spectrum Pharmaceuticals (SPPI) Receiving Positive News Coverage, Report Shows
www.americanbankingnews.com - April 30 at 10:42 AM |
| Spectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care Conference on May 4
finance.yahoo.com - April 27 at 3:34 PM |
| Spectrum Pharmaceuticals (SPPI) Earns News Impact Rating of 0.22
www.americanbankingnews.com - April 25 at 7:07 PM |
| Spectrum Pharmaceuticals (SPPI) Receiving Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 21 at 10:18 PM |
Spectrum Pharmaceuticals (SPPI) Chart for Saturday, August, 19, 2017
